Connection

Co-Authors

This is a "connection" page, showing publications co-authored by CHANTALE BERNATCHEZ and JENNIFER WARGO.
Connection Strength

1.079
  1. Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers (Basel). 2021 Oct 22; 13(21).
    View in: PubMed
    Score: 0.210
  2. Novel Treatments in Development for Melanoma. Cancer Treat Res. 2016; 167:371-416.
    View in: PubMed
    Score: 0.141
  3. Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res. 2023 01 04; 29(1):154-164.
    View in: PubMed
    Score: 0.057
  4. Multi-modal molecular programs regulate melanoma cell state. Nat Commun. 2022 07 09; 13(1):4000.
    View in: PubMed
    Score: 0.055
  5. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature. 2021 04; 592(7852):138-143.
    View in: PubMed
    Score: 0.050
  6. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.050
  7. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun. 2020 04 15; 11(1):1839.
    View in: PubMed
    Score: 0.047
  8. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 2020 01 30; 11(1):603.
    View in: PubMed
    Score: 0.047
  9. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019 01 29; 116(5):1692-1697.
    View in: PubMed
    Score: 0.043
  10. Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. Cancer Discov. 2018 11; 8(11):1366-1375.
    View in: PubMed
    Score: 0.042
  11. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.
    View in: PubMed
    Score: 0.042
  12. The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clin Cancer Res. 2018 07 15; 24(14):3366-3376.
    View in: PubMed
    Score: 0.041
  13. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. 2017 10; 7(10):1088-1097.
    View in: PubMed
    Score: 0.039
  14. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Oncoimmunology. 2017; 6(6):e1321187.
    View in: PubMed
    Score: 0.039
  15. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017; 2.
    View in: PubMed
    Score: 0.038
  16. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
    View in: PubMed
    Score: 0.037
  17. Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9.
    View in: PubMed
    Score: 0.037
  18. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
    View in: PubMed
    Score: 0.035
  19. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012 Oct 01; 18(19):5329-40.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.